赛诺菲通过收购plromed扩大其生物外科部门

Pharmadeals Review Pub Date : 2012-03-26 DOI:10.3833/pdr.v2012i3.1705

Heather Cartwright

{"title":"赛诺菲通过收购plromed扩大其生物外科部门","authors":"Heather Cartwright","doi":"10.3833/pdr.v2012i3.1705","DOIUrl":null,"url":null,"abstract":"Sanofi has agreed to buy the US medical device company Pluromed in order to strengthen the biosurgery portfolio it gained via its takeover of Genzyme in 2011. With the acquisition, Sanofi will gain Pluromed’s biocompatible reverse thermosensitive polymer technology, Rapid Transition Polymers™, and LeGoo® gel, which was approved by the US FDA in September 2011 and which provides temporary blood vessel occlusion during surgery","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"51 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sanofi Augments its Biosurgery Unit with Pluromed Acquisition\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/pdr.v2012i3.1705\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Sanofi has agreed to buy the US medical device company Pluromed in order to strengthen the biosurgery portfolio it gained via its takeover of Genzyme in 2011. With the acquisition, Sanofi will gain Pluromed’s biocompatible reverse thermosensitive polymer technology, Rapid Transition Polymers™, and LeGoo® gel, which was approved by the US FDA in September 2011 and which provides temporary blood vessel occlusion during surgery\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"51 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-03-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/pdr.v2012i3.1705\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/pdr.v2012i3.1705","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

赛诺菲已同意收购美国医疗器械公司plromed，以加强其通过2011年收购健赞(Genzyme)获得的生物外科产品组合。通过此次收购，赛诺菲将获得plromed的生物相容性反向热敏聚合物技术，Rapid Transition Polymers™和LeGoo®凝胶，该技术于2011年9月获得美国FDA批准，可在手术期间提供临时血管阻塞

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Sanofi Augments its Biosurgery Unit with Pluromed Acquisition

Sanofi has agreed to buy the US medical device company Pluromed in order to strengthen the biosurgery portfolio it gained via its takeover of Genzyme in 2011. With the acquisition, Sanofi will gain Pluromed’s biocompatible reverse thermosensitive polymer technology, Rapid Transition Polymers™, and LeGoo® gel, which was approved by the US FDA in September 2011 and which provides temporary blood vessel occlusion during surgery

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pharmadeals Review

自引率

0.00%

发文量